Abstract: The subject matter disclosed herein relates to methods for diagnosing a neurological disorder in a subject. In certain aspects, the methods described herein involve determining one or more critical areas in the brain from molecular Magnetic Resonance Imaging (MRI) data where two groups differ and measuring MRI signal within determined critical areas in a new subject in order to assign risk or diagnosis.

Abstract: The subject matter disclosed herein relates to methods for diagnosing a neurological disorder in a subject. In certain aspects, the methods described herein involve determining one or more critical areas in the brain from PET data where two groups differ and measuring PET signal within determined critical areas in a new subject in order to assign risk or diagnosis.

Abstract: The present disclosure is directed to iterative regularized reconstruction methods. In certain embodiments, the methods incorporate locally-weighted total variation denoising to suppress artifacts induced by PSF modeling. In certain embodiments, the methods are useful for suppressing ringing artifacts while contrast recovery is maintained. In certain embodiments, the weighting scheme can be extended to noisy measures introducing a noise-independent weighting scheme. The present disclosure is also directed to a method for quantifying radioligand binding in a subject without collecting arterial blood. In certain embodiments, the methods incorporate using imaging data and electronic health records to predict one or more anchors, which are used to generate an aterial input function (AIF) for the radioligand.

Abstract: The present invention provides a method of determining whether a subject is afflicted with a depressive disorder comprising: (i) introducing into the subject a positron emission tomography (PET) radioligand capable of binding with a serotonin 5-HT1A receptor; (ii) performing one or more PET scans of the subject; (iii) determining, by analysis of the one or more PET images, a receptor binding potential of the PET radioligand for the serotonin 5-HT1A receptor in a region of interest in the subject; (iv) comparing the receptor binding potential value of the PET radioligand in the region of interest in the subject to a predetermined receptor binding potential threshold value; and (v) classifying the subject as having the depressive disorder or as not having the depressive disorder based on the comparison of step (iv), thereby determining whether the subject is afflicted with the depressive disorder.

Abstract: The present disclosure is directed to iterative regularized reconstruction methods. In certain embodiments, the methods incorporate locally-weighted total variation denoising to suppress artifacts induced by PSF modeling. In certain embodiments, the methods are useful for suppressing ringing artifacts while contrast recovery is maintained. In certain embodiments, the weighting scheme can be extended to noisy measures introducing a noise-independent weighting scheme. The present disclosure is also directed to a method for quantifying radioligand binding in a subject without collecting arterial blood. In certain embodiments, the methods incorporate using imaging data and electronic health records to predict one or more anchors, which are used to generate an aterial input function (AIF) for the radioligand.

Abstract: The subject matter disclosed herein relates to methods for diagnosing a neurological disorder in a subject. In certain aspects, the methods described herein involve determining one or more critical areas in the brain from PET data where two groups differ and measuring PET signal within determined critical areas in a new subject in order to assign risk or diagnosis.

Abstract: The subject matter disclosed herein relates to methods for diagnosing a neurological disorder in a subject. In certain aspects, the methods described herein involve determining one or more critical areas in the brain from molecular Magnetic Resonance Imaging (MRI) data where two groups differ and measuring MRI signal within determined critical areas in a new subject in order to assign risk or diagnosis.

Abstract: The subject matter disclosed herein relates to methods for diagnosing a neurological disorder in a subject. In certain aspects, the methods described herein involve determining one or more critical areas in the brain from PET data where two groups differ and measuring PET signal within determined critical areas in a new subject in order to assign risk or diagnosis.

Abstract: The subject matter disclosed herein relates to methods for diagnosing a neurological disorder in a subject. In certain aspects, the methods described herein involve determining one or more critical areas in the brain from PET data where two groups differ and measuring PET signal within determined critical areas in a new subject in order to assign risk or diagnosis.